Heparin-binding epidermal growth factor-like growth factor as a new target molecule for cancer therapy

Advances in Experimental Medicine and Biology

Volumn 622, Issue , 2008, Pages 281-295

  Miyamoto, Shingo ^a   Yagi, Hiroshi ^a   Yotsumoto, Fusanori ^a   Kawarabayashi, Tatsuhiko ^a   Mekada, Eisuke ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; BETA CELLULIN; CETUXIMAB; COLLAGEN TYPE 1; DIPHTHERIA TOXOID CRM197; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIREGULIN; ERLOTINIB; FIBRONECTIN; GEFITINIB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MATUZUMAB; NEU DIFFERENTIATION FACTOR; PACLITAXEL; PANITUMUMAB; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; CANCER THERAPY; CELL ADHESION; CELL SURVIVAL; FEVER; FLU LIKE SYNDROME; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIGAND BINDING; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR BINDING; REVIEW;

EID: 84934443762     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-68969-2_23     Document Type: Review

References (55)

1. Athale CA, Deisboeck TS. The effects of EGF-receptor density on multiscale tumor growth patterns. J Theor Biol 2006, 238:771-779
2. Azemar M, Schmidt M, Arlt F, Kennel P, Brandt B, Papadimitriou A, Groner B, Wels W. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vitro. Int J Cancer 2000, 86:269-275
3. Buter J, Giaccone G. EGFR inhibitors in lung cancer. Oncology (willston Park) 2005, 19:1707-1711
4. Buzzi S. Diphtheria toxin treatment of human advanced cancer. Cancer Res 1982, 42:2054-2058
5. Buzzi S, Rubboli D, Buzzi G, Buzzi AM, Morisi C, Pironi F. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol Immunother 2004, 53:1041-1048
6. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J, Aaronson SA. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 1987, 51:1063-1070
7. Downward J, Yarden Y, Mayer E, Scrace G, Totty N, Stockwell P, Ullich A, Schlessinger J, Waterfield MD. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984, 307:521-527
8. El-Obeid A, Hesselager G, Westermark B, Nister M. TGF-alpha-driven tumor growth is inhibited by an EGF receptor tyrosine kinase inhibitor. Biochem Biophys Res Commun 2002, 290:349-358
9. Fischer OM, Hart S, Gschwind A, Ullrich A. EGFR signal transactivation in cancer cells. Biochem Soc Trans 2003, 31(Pt 6):1203-1208
10. Friday BB, Adjei AA. K-ras as a target for cancer therapy. Biochem Biophys Acta (2005), 1756:127-144
11. Gangarosa LM, Sizemore N, Graves-Deal R, Oldham SM, Der CJ, Coffey RJ. A rafindependent epidermal growth factor receptor autocrine loop is necessary for ras transformation of rat intestinal epithelial cells. J Biol Chem (1997) 272:18926-18931
12. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun MA. Heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991, 251:936-939
13. Higashiyama S, Iwamoto R, Goishi K, Raab G, Taniguchi N, Klagsbrun M, Mekada E. The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol 1995, 128:929-938
14. Ito Y, Takeda T, Higashiyama S, Sakon M, Wakasa KI, Tsujimoto M, Monden M, Matsuura N. Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol Rep 2001, 8(4):903-907
15. Ito Y, Higashiyama S, Takeda T, Yamamoto Y, Wakasa KI, Matsuura N. Expression of heparin-binding epidermal growth factor-like growth factor in pancreatic adenocarcinoma. Int J Pancreatol 2001, 29:47-52
16. Iwamoto R, Higashiyama S, Mitamura T, Taniguchi N, Klagsbrun M, Mekada E. Heparinbinding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity. EMBO J 1994, 13:2322-2330
17. Iwamoto R, Mekada E. Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev 2000, 11(4):335-344
18. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI. Insulin-like growth factor-I receptor signaling and acquired resistance to gefitinib (ZD1839); Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004, 11:793-814
19. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P, Korc M. Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1994, 202(3):1705-1709
20. Krug U, Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 2002, 21:3475-3495
21. Lin J, Hutchinson L, Gaston SM, Raab G, Freeman MR. BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor: a unique role for proHB-EGF in cell survival regulation. J Biol Chem 2001, 276:30127-30132
22. Lu Y, Zi X, Zhao Y, Mascarrenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93:1852-1857
23. Mills GB, May C, McGill M, Roifman CM, Mellers A. A putative new growth factor in ascetic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 1988, 48:1066-1071
24. Mitamura T, Higashiyama S, Taniguchi N, Klgasbrun M, Mekada E. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 1995, 270:1015-1019
25. Miyamoto S, Yagi H, Yotsumoto F, Kawarabayashi T, Mekada E. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci 2006, 97(5):341-347
26. Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M, Kanoh H, Nakano H, Mekada E. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004, 64:5720-5727
27. Morgillo F, Lee HY. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Updat 2005, 8:298-310
28. Naef M, Yokoyama M, Friess H, Buchler MW, Korc M. Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer 1996, 66(3):315-321
29. Nakamura K, Iwamoto R, Mekada E. Membrane-anchored heparin-binding EGF-like growth factor (HB-EGF) and diphtheria toxin receptor-associated protein (DRAP27)/CD9 form a complex with integrin alpha 3 beta 1 at cell-cell contact sites. J Cell Biol 1995, 129: 1691-1705
30. Nanba D, Mammoto A, Hashimoto K, Higashiyama S. Proteolytic release of the carboxyterminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 2003, 163:489-502
31. Nanba D, Higashiyama S. Dual intracellular signaling by proteolytic cleavage of membraneanchored heparin-binding EGF-like growth factor. Cytokine Growth Factor Rev 2004, 15(1):13-19
32. Nishi E, Klagsbrun M. Heparin-binding epidermal growth factor-like growth factor (HBEGF) is a mediator of multiple physiological and pathological pathways. Growth Factors 2004, 22(4):253-260
33. Normanno N, Selvam MP, Saeki T, Qi C, Johnson GR, Kim N, Ciardiello F, Shoyab M, Plowman GD, Todaro GJ, Salmon DS. Amphiregulin as an autocrine growth factor for c-Ha-rasand c-erbB-2-transformed human mammary epithelial cells, Proc Natl Acad Sci USA (1994), 91:2790-2794
34. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003, 10(1):1-21
35. Raab G, Klagsbrun M Heparin-binding EGF-like growth factor. Biochimica et Biophysica Acta 1997, 1333(3):F179-F199
36. Ramnarain DB, Park S, Lee DY, Hatnpaa KJ, Scoggin SO, Out H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 2006, 66:867-874
37. Riese DJ, II, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998, 20(1):41-48
38. Roudabush FL, Pierce KL, Maudsley S, Khan KD, Luttrell LM. Transactivation of the EGF receptor mediates IGF-I-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 2000, 275:22583-22589
39. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19(3):183-232
40. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004, 306(5701):1506-1507
41. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003, 17(1):7-30
42. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A. The complexity of targeting EGFR signaling in cancer: from expression and turnover. Biochem Biophys Acta 2006, 1766:120-139
43. Settleman J. Inhibition of mutant EGF receptors by gefitinib: targeting an achilles' heel of lung cancer. Cell Cycle 2004, 3:1496-1497
44. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167
45. Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. N Engl J Med 1980, 303:878-880
46. Suganuma K, Kubota T, Saikawa Y, Abe S, Otani Y, Furukawa T, Kumai K, Hasegawa H, Watanabe M, Kitajima M, Nakayama H, Okabe H. Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray. Cancer Sci 2003, 94:355-359
47. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell 1995, 80:279-284
48. Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E, Nakano H. Clinical significance of heparin-binding EGF (epidermal growth factor)-like growth factor and ADAM (a disintegrin and metalloprotease) 17 expression in human ovarian cancer. Clin Cancer Res 2005, 11:4783-4792
49. Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001, 61:6227-6233
50. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yagen Y. A hierarchial network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996, 16:5276-5287
51. Wang F, Liu R, Lee SW, Sloss CM, Couget J, Cusack JC. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene, in press
52. Wong AJ, Ruppert JM, Binger SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992, 89:2965-2969
53. Yamazaki S, Iwamoto R, Saeki K, Asakura M, Takashima S, Yamazaki A, Kimura R, Mizushima H, Moribe H, Higashiyama S, Endoh M, Kaneda Y, Takagi S, Itami S, Takeda N, Yamada G, Mekada E. Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities. J Cell Biol 2003, 163:469-475
54. Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, Iwamoto R, Mekada E, Nakano H. Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Brit J Cancer 2005, 92:1737-1745
55. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001, 2(2):127-137